Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain
30.10.2025 13:43
Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.
My Top 10 High-Yield Picks For November 2025: One Yields 9%+
30.10.2025 13:33
These top high-yield dividend stocks provide income and growth. Learn how diversified picks like CVX, VZ, MO & ARCC can boost your portfolio.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
30.10.2025 11:45
Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Merck narrows full-year sales guidance
30.10.2025 11:07
Investing.com - Merck has narrowed its full-year sales forecast, as a boost from an amended collaboration agreement with peer AstraZeneca and lower tariff costs was mitigated by costs connected to its purchase of Verona Pharma.
Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time.
30.10.2025 10:51
Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.
Merck: Q3 Earnings Snapshot
30.10.2025 10:48
RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Thursday reported third-quarter earnings of $5.79 billion. The Rahway, New Jersey-based company said it had net income of $2.32 per share. Earnings, adjusted for one-time gains and costs, came to $2.58 per share.
Merck Profit Rises on Strong Keytruda Demand
30.10.2025 10:41
Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise.
Merck & Co., Inc. 2025 Q3 - Results - Earnings Call Presentation
30.10.2025 10:01
2025-10-30. The following slide deck was published by Merck & Co., Inc.
Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge
30.10.2025 09:20
Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.
Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN)
30.10.2025 08:56
We recently published 11 Stocks Jim Cramer Discussed, Including A Potential “Worst Stock Ever”. Organon & Co. (NYSE:OGN) is one of the stocks Jim Cramer recently discussed. Organon & Co. (NYSE:OGN) is a women’s health company that provides fertility and contraceptive products. It’s been caught in a wave of controversy lately after CEO Kevin Ali […]
Merck (MRK) Reports Earnings Tomorrow: What To Expect
29.10.2025 03:16
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.
3 Dividend-Paying Drug Stocks to Buy at a Discount
27.10.2025 18:00
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?
Are You Looking for a High-Growth Dividend Stock?
27.10.2025 15:45
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
27.10.2025 15:32
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
27.10.2025 13:15
Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities
27.10.2025 12:33
Organon (OGN) said Monday its board has appointed the company's head of manufacturing and supply Jos
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
27.10.2025 10:45
RAHWAY, N.J., October 27, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg. WINREVAIR, an activin signaling inhibitor, is now FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise
Merck's Winrevair gets expanded indication in US
27.10.2025 09:23
Merck has announced that the US FDA has approved an update to the label for Winrevair, an activin signaling inhibitor, based on the Phase 3 ZENITH trial in the treatment of pulmonary arterial...
Merck’s oncology prospects could portend a post-Keytruda future
27.10.2025 08:00
Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?